Kamila Pritam, Kar Koyel, Chowdhury Sailee, Chakraborty Priyanka, Dutta Ria, S Sowmiya, Singh S Ankul, Prajapati Bhupendra Gopalbhai
BCDA College of Pharmacy & Technology, Department of Pharmaceutical Chemistry, 78/1- Jessore Road (South), Hridaypur, Kolkata, West Bengal 700127, India.
Department of Pharmacology, Faculty of Pharmacy, Dr. M.G.R Educational and Research Institute, Velappanchavadi, Chennai, Tamil Nadu 600077, India.
IBRO Neurosci Rep. 2025 May 22;18:771-782. doi: 10.1016/j.ibneur.2025.05.005. eCollection 2025 Jun.
Alzheimer's disease (AD) is increasingly recognized as a disorder not solely of amyloid and tau accumulation but also of chronic immune dysregulation. Emerging evidence highlights the critical role of neuroinflammation, characterized by sustained activation of microglia and astrocytes, cytokine release, and inflammasome activation in accelerating AD progression. Genome-wide studies have further identified key inflammatory genes and immune pathways associated with increased disease risk. This review critically evaluates the mechanistic underpinnings of neuroinflammation in AD, focusing on glial cell behavior, immune signaling, and their contribution to neuronal dysfunction. Importantly, the review highlights recent advances in anti-inflammatory therapeutic approaches, including modulators of IL-1β, TNF-α, TREM2, and CB2 pathways. By integrating mechanistic and therapeutic insights, this work underscores the potential of immunomodulatory strategies as viable interventions in AD and provides a novel framework for future research in targeted anti-neuroinflammatory treatments.
阿尔茨海默病(AD)越来越被认为不仅是一种淀粉样蛋白和tau蛋白积累的疾病,也是一种慢性免疫失调的疾病。新出现的证据突出了神经炎症的关键作用,其特征是小胶质细胞和星形胶质细胞的持续激活、细胞因子释放以及炎性小体激活,这些在加速AD进展中发挥作用。全基因组研究进一步确定了与疾病风险增加相关的关键炎症基因和免疫途径。本综述批判性地评估了AD中神经炎症的机制基础,重点关注胶质细胞行为、免疫信号传导及其对神经元功能障碍的影响。重要的是,该综述突出了抗炎治疗方法的最新进展,包括白细胞介素-1β、肿瘤坏死因子-α、触发受体表达于髓样细胞2(TREM2)和大麻素受体2(CB2)途径的调节剂。通过整合机制和治疗方面的见解,这项工作强调了免疫调节策略作为AD可行干预措施的潜力,并为未来靶向抗神经炎症治疗的研究提供了一个新的框架。